Free Shipping on orders over $150
1
Awaiting product image

BPC-157 / TB-500 — 5mg / 5mg (injectable)

Pentadecapeptide / Gastric Origin

BPC-157 is a synthetic peptide carrying an active body of indexed research literature, with 222 PubMed records to date spanning 156 animal studies, 49 human studies, and 2 clinical studies.

$65.00

BPC-157 is a pentadecapeptide (15 amino acid sequence) derived from a protective protein found naturally in human gastric juice. In preclinical studies, it accelerates healing of

SKU: LL-BPCTB-55 Category:

PubMed Literature Index

222

studies indexed in the public literature

Q2 2026 · view PubMed search ↗

49
Human
156
Animal
2
Clinical Trials
0
EU Trials

Overview

In the literature, BPC-157 is described not as a classical receptor agonist binding a single defined target, but as a proposed biological signaling orchestrator. Studies describe upregulation of receptor expression, activation of downstream signaling cascades, and modulation of neurotransmitter receptor sensitivity as components of this proposed activity. Researchers characterize this as a multi-pathway mechanism, distinguishing it from single-target receptor pharmacology and framing its study across multiple tissue types rather than one isolated system.

Chemical & Molecular Properties

FormulaC62H98N16O22
Mol. Weight1419.5 g/mol
PubChem CID9941957

Key Areas of Research Interest

  • Investigated in the context of receptor expression regulation
  • Investigated in the context of downstream intracellular signaling cascade activation
  • Investigated in the context of neurotransmitter receptor sensitivity modulation
  • Investigated in the context of multi-tissue, multi-pathway signaling rather than single-target activity
  • Subject of a substantial indexed literature base, including preclinical (animal) and limited clinical human studies

FAQ

What is BPC-157 commonly researched for?

BPC-157 is studied in the literature for its proposed role as a multi-pathway biological signaling orchestrator, including research into receptor expression regulation, downstream signaling cascade activation, and neurotransmitter receptor sensitivity, across a body of 222 indexed PubMed records spanning animal and human studies. It is sold strictly for laboratory research use, not for human or animal consumption.

Is BPC-157 FDA-approved?

No. Sold for laboratory research use only, not FDA-approved, not for human or veterinary consumption.

How is BPC-157 stored?

Lyophilized and frozen, protected from light; refrigerated after reconstitution for research use.

What purity standard does Legendary Labz hold BPC-157 to?

Every lot of BPC-157 is independently third-party tested to verify purity and identity before release.

Is a Certificate of Analysis available for BPC-157?

Yes. Certificates of Analysis are published per lot as testing completes, and Legendary Labz is Sourced in the USA.

Materials referenced on this page are intended for laboratory research purposes. No claims regarding therapeutic efficacy are made or implied. Not for human or veterinary use. Not evaluated by the FDA. Must be 21+.

Description

Overview

This research preparation combines BPC-157 and TB-500.

BPC-157 is a pentadecapeptide (15 amino acid sequence) derived from a protective protein found naturally in human gastric juice. In preclinical studies, it accelerates healing of tendons, ligaments, muscle, and gut tissue by upregulating growth hormone receptors, promoting angiogenesis, and modulating nitric oxide pathways. It acts locally with a systemic amplification effect. Human pilot data (n<30 across all studies) suggests promise for musculoskeletal and GI applications, but large-scale RCTs have not been completed. Regulatory status has changed significantly since 2022.

TB-500 is a synthetic version of a fragment of Thymosin Beta-4 (Tβ4), found in virtually all human and animal cells. IMPORTANT: TB-500 (the synthetic fragment) is distinct from TB4 (the full endogenous protein), they should not be used interchangeably. In animal models, TB-500 promotes actin regulation, accelerates healing of muscle, tendon, ligament, and cardiac tissue, and reduces inflammation. No human RCTs exist for TB-500 specifically. TB4 showed promise in a 2009 Phase 2 trial, but results have never been published. Frequently stacked with BPC-157 in practitioner protocols.

Structure & Chemistry

  • Category: SYSTEMIC REPAIR / GI HEALING
  • Molecular size: ~1.8 kDa (small peptide)

Regulatory & Research Status

  • FDA CATEGORY 2 (2023): Cannot be legally compounded in the US for commercial use, availability is restricted.
  • WADA PROHIBITED (2022): Listed under S0 Non-Approved Substances, banned in competitive sports.
  • HUMAN EVIDENCE LIMITED: Only 3 small pilot studies (<30 total participants) exist; no completed Phase 2/3 RCTs.
  • All benefits listed below are primarily from animal/in vitro studies. Human clinical confirmation is pending.
  • Dosing protocol is practitioner-derived, not established by clinical trials.
  • REGULATORY UPDATE (June 2026): On April 16, 2026, FDA convened the Pharmacy Compounding Advisory Committee (PCAC) to evaluate substances nominated for the 503A Bulk Drug Substances list (FR 2026-07361). No compound status changes affecting this substance have been published from this meeting as of June 2026. Monitor fda.gov for finalized outcomes.
  • WADA PROHIBITED: TB-500 and Thymosin Beta-4 are banned under S2 Peptide Hormones in competitive sports.
  • NO HUMAN CLINICAL TRIALS: Zero published RCTs specifically on TB-500 (the synthetic fragment).
  • TB-500 ≠ TB4: TB-500 is a synthetic fragment; Thymosin Beta-4 (TB4) is the full endogenous protein.
  • TB4 Phase 2 trial (2009): Completed but results were NEVER published, a significant data gap after 15+ years.
  • Dosing is practitioner-derived; 2024 research suggests activity may derive partly from metabolite breakdown, not direct TB4 mechanism.

Specifications

Presentation 5mg single vial
Purity >99% by HPLC
Form Lyophilized powder (reconstitute with bacteriostatic water for laboratory use)
Category SYSTEMIC REPAIR / GI HEALING
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.

Reviews

There are no reviews yet.

Be the first to review “BPC-157 / TB-500 — 5mg / 5mg (injectable)”

Your email address will not be published. Required fields are marked *

Overview

This research preparation combines BPC-157 and TB-500.

BPC-157 is a pentadecapeptide (15 amino acid sequence) derived from a protective protein found naturally in human gastric juice. In preclinical studies, it accelerates healing of tendons, ligaments, muscle, and gut tissue by upregulating growth hormone receptors, promoting angiogenesis, and modulating nitric oxide pathways. It acts locally with a systemic amplification effect. Human pilot data (n<30 across all studies) suggests promise for musculoskeletal and GI applications, but large-scale RCTs have not been completed. Regulatory status has changed significantly since 2022.

TB-500 is a synthetic version of a fragment of Thymosin Beta-4 (Tβ4), found in virtually all human and animal cells. IMPORTANT: TB-500 (the synthetic fragment) is distinct from TB4 (the full endogenous protein), they should not be used interchangeably. In animal models, TB-500 promotes actin regulation, accelerates healing of muscle, tendon, ligament, and cardiac tissue, and reduces inflammation. No human RCTs exist for TB-500 specifically. TB4 showed promise in a 2009 Phase 2 trial, but results have never been published. Frequently stacked with BPC-157 in practitioner protocols.

Structure & Chemistry

  • Category: SYSTEMIC REPAIR / GI HEALING
  • Molecular size: ~1.8 kDa (small peptide)

Regulatory & Research Status

  • FDA CATEGORY 2 (2023): Cannot be legally compounded in the US for commercial use, availability is restricted.
  • WADA PROHIBITED (2022): Listed under S0 Non-Approved Substances, banned in competitive sports.
  • HUMAN EVIDENCE LIMITED: Only 3 small pilot studies (<30 total participants) exist; no completed Phase 2/3 RCTs.
  • All benefits listed below are primarily from animal/in vitro studies. Human clinical confirmation is pending.
  • Dosing protocol is practitioner-derived, not established by clinical trials.
  • REGULATORY UPDATE (June 2026): On April 16, 2026, FDA convened the Pharmacy Compounding Advisory Committee (PCAC) to evaluate substances nominated for the 503A Bulk Drug Substances list (FR 2026-07361). No compound status changes affecting this substance have been published from this meeting as of June 2026. Monitor fda.gov for finalized outcomes.
  • WADA PROHIBITED: TB-500 and Thymosin Beta-4 are banned under S2 Peptide Hormones in competitive sports.
  • NO HUMAN CLINICAL TRIALS: Zero published RCTs specifically on TB-500 (the synthetic fragment).
  • TB-500 ≠ TB4: TB-500 is a synthetic fragment; Thymosin Beta-4 (TB4) is the full endogenous protein.
  • TB4 Phase 2 trial (2009): Completed but results were NEVER published, a significant data gap after 15+ years.
  • Dosing is practitioner-derived; 2024 research suggests activity may derive partly from metabolite breakdown, not direct TB4 mechanism.

Specifications

Presentation 5mg single vial
Purity >99% by HPLC
Form Lyophilized powder (reconstitute with bacteriostatic water for laboratory use)
Category SYSTEMIC REPAIR / GI HEALING
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.

Related Research

Related products